Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Bakuchiol

Also known as: bakuchiol skincare

Bakuchiol is a plant-derived compound used in skincare for visible lines and uneven pigmentation. It is chemically different from retinol, although laboratory work has found some similar effects on skin-cell activity.

In plain English — Bakuchiol is a skincare ingredient studied for improving facial lines and uneven colour. A small study of one cream found improvement over twelve weeks, with less stinging and scaling than the retinol cream it was compared with. Results depend on the product, and the ingredient can still cause a skin reaction.

Evidence status

Emerging

A small randomised facial study supports improvement with a particular bakuchiol cream; other studies often examine multi-ingredient formulations. A systematic review found substantial design limitations and could not pool the results.

What bakuchiol is, and the types available#

Bakuchiol is a meroterpene phenol found in plants including Psoralea corylifolia, commonly called babchi. In skincare it is incorporated into finished creams and other topical formulations. Its identity is distinct from the whole plant extract: an ingredient name, a plant oil and a finished product are three different things.[1, 2]

Single-active and combination formulations have both been studied. Combination products may include other ingredients directed at pigmentation, acne or skin comfort, making the whole formula the relevant unit of evidence. The subject here is topical bakuchiol; see retinoids for the vitamin A family and photoageing for the wider clinical context.[3][4]

Use of bakuchiol in aesthetic practice#

The clearest cosmetic use is for a client concerned about facial photodamage, particularly fine lines and uneven colour. Relevant assessment includes the exact concern, previous product reactions, current skincare and any prescribed skin treatment. The decision is whether a particular formulation offers a useful, tolerable addition, with a defined appearance outcome to review.[1, 3, 4, 6]i

For acne-prone clients, coordinated supportive skincare is a separate role from deciding medical acne treatment. A combination product may be an adjunct, but substituting an ingredient name for the client’s prescribed regimen goes beyond the evidence discussed here.[4][6, 7]

Contraindications and cautions#

Known allergy to an ingredient in the product, or an unresolved reaction following its use, requires avoidance of that suspected trigger and appropriate assessment. The full formula matters: symptoms cannot automatically be attributed to bakuchiol rather than another constituent.[5, 6]i

For pregnancy and breastfeeding, this review did not identify human outcome studies establishing topical bakuchiol’s safety. That is uncertainty, not evidence of fetal harm. “Plant-derived” is not sufficient grounds to provide a pregnancy-safety assurance; product-specific decisions belong with the person’s maternity or prescribing clinician.[no source found]

Clinical uses and the evidence behind them#

Facial photoageing

A single-centre, double-blind study randomised 44 healthy adults aged 31–56 to a 0.5% bakuchiol cream twice daily or 0.5% retinol cream nightly for 12 weeks. Both improved photographic wrinkle-area and pigmentation measurements; no significant between-group efficacy difference was found. Seven participants left, with all 44 included in the intention-to-treat analysis. The unequal frequency describes the study, not a suggested routine.[1]

The study was university-funded; Sytheon formulated the creams, and the senior author disclosed commercial advisory/consultancy relationships. Its positive cosmetic findings are useful but belong to those formulations and that short facial study.[1]i

Acne and pigmentary concerns

A Bioderma-funded trial enrolled 111 participants, mainly with mild-to-moderate facial acne, in a 56-day comparison of prescribed adapalene plus either a multi-active cream or vehicle. The active cream included bakuchiol, ginkgo, mannitol and other actives. Inflammatory lesions improved more with that combination; non-inflammatory lesion improvement did not differ significantly. Three authors were Bioderma employees.[4]

Across indications, the 2024 systematic review found 15 trials: 12 uncontrolled/open-label and 10 involving combination therapies. It identified substantial bias concerns and judged pooling inappropriate. These overlapping counts are trial characteristics, not separate groups or patient response rates. Its search ended in August 2022.[3]

Selecting bakuchiol#

Useful selection questions concern the exact ingredient, concentration, vehicle, other actives and evidence for the desired outcome. A supplier ingredient dossier and a trial of the final product answer different questions. Tolerability history and compatibility with a clinician-directed treatment plan matter alongside any comparative photograph.[1, 3, 4, 6]i

The comparative facial study used highly purified, psoralen-depleted bakuchiol. Its results do not establish interchangeability with an unspecified babchi extract or oil. Where the product differs materially from the studied formula, describe the evidence as ingredient-level context rather than a demonstrated result for that product.[1]i

Adverse effects and their management#

Stinging, scaling and redness were assessed in the facial trial; scaling and stinging were greater with the retinol comparator. Better relative tolerability is useful information, not a guarantee of comfort. Contact dermatitis to bakuchiol in a cosmetic cream has also been reported.[1][5, 6]i

A new itchy, blistered, dry or cracked eruption warrants attention to the suspect product and other exposures. Avoiding the causal irritant or allergen is central to contact-dermatitis management. Persistent, recurrent or severe symptoms need medical assessment, rather than continued exposure to prove that the skin will adjust.[6, 7]

Referral and scope boundaries#

Cosmetic product discussion does not replace diagnosis. For dermatitis, a GP may arrange specialist assessment when the trigger is unclear or symptoms resist treatment. For acne, pharmacy advice is appropriate for mild disease; moderate/severe acne, nodules or cysts, unsuccessful initial treatment or substantial distress merit GP review.[6, 7]

The acne vulgaris and hyperpigmentation entries provide the relevant assessment context. A change to prescribed treatment requires the treating clinician’s involvement, not an inference from a cosmetic ingredient comparison.[4]

Mechanism of action#

Supplier-affiliated work used reconstructed full-thickness skin and cultured human dermal fibroblasts to examine gene expression and collagen-related signals. Bakuchiol and retinol produced overlapping patterns in those laboratory systems, supporting a biological rationale for further clinical study. These were human-derived cells and constructed tissue, not a treatment trial in living human faces.[2]

The authors proposed retinol-like regulation of gene expression. That is a useful account of the experimental finding, with mechanism and visible clinical outcomes remaining different levels of evidence.[2]

Commonly misstated claims#

“Bakuchiol is natural retinol”

Claim heard: Bakuchiol is a botanical form of the same molecule.

Literature finding: The chemical structures differ; the comparison arose from overlapping experimental activity.[1, 2]

Supported statement: Bakuchiol is a distinct compound with some retinol-like laboratory effects.

“The trial proved equivalence to retinoids”

Claim heard: The comparative study establishes interchangeable efficacy across the retinoid family.

Literature finding: Its authors concluded that the tested bakuchiol cream was comparable and better tolerated. A nonsignificant difference in this small comparison is not a class-wide equivalence test.[1]i

Supported statement: The study supports a promising product-specific comparison with retinol, not equivalence to prescription retinoids.

“The facial study demonstrated new collagen”

Claim heard: The retinol-comparison trial directly measured collagen production.

Literature finding: The authors explicitly describe cosmetic assessment without measurement of collagen production.[1]

Supported statement: Its results concern visible appearance; the collagen-related rationale comes from separate laboratory work.

Areas of remaining uncertainty#

  • Persistence of benefit: Short follow-up provides limited information about maintenance or outcomes after stopping; consultation should avoid promising a durable endpoint.[1]i[3]
  • Product-to-product transfer: Combination formulas and varied study designs prevent a reliable ingredient-wide effect estimate; match the claim to the actual product.[3]
  • Population coverage: The comparative study involved generally healthy adults, so its findings do not establish treatment outcomes in inflammatory skin disease.[1]

Frequently asked questions#

What concern is bakuchiol most directly studied for?

Facial photoageing, including lines and uneven pigmentation. The comparative trial is discussed under clinical uses, with the formulation, population and duration attached.[1]

Is there a single best bakuchiol product?

The retrieved evidence does not support a universal product ranking. Selection depends on the formula, its evidence, the intended appearance outcome and the client’s tolerance history.[1, 3, 4, 6]i

Can it fit alongside prescribed acne care?

Potentially as supportive skincare, with the treating clinician involved. The adjunctive study tested a particular multi-active cream, described above; it is not a reason to replace a prescribed treatment.[4][6, 7]

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. Dhaliwal S, Rybak I, Ellis SR, et al. Prospective, randomized, double-blind assessment of topical bakuchiol and retinol for facial photoageing. British Journal of Dermatology. 2019;180(2):289–296. doi:10.1111/bjd.16918.Tier 2Supports: Single-centre, 12-week facial comparison in 44 randomised healthy adults; cosmetic outcomes, tolerability, formulation identity and exclusions.Funding / interest: University of California–Davis Department of Dermatology funded the study. Sytheon formulated the products. R K Sivamani disclosed advisory work for Dermveda and consultancy for Burt's Bees and Dermala.
  2. Chaudhuri RK, Bojanowski K. Bakuchiol: a retinol-like functional compound revealed by gene expression profiling and clinically proven to have anti-aging effects. International Journal of Cosmetic Science. 2014;36(3):221–230. doi:10.1111/ics.12117. PMID:24471735.In vitroTier 3Supports: Chemical identity and laboratory gene-expression/collagen findings in EpiDerm FT reconstructed skin and cultured human fibroblasts. Only those laboratory findings are used; the abstract also describes a clinical case study.Funding / interest: Chaudhuri was affiliated with ingredient supplier Sytheon; Bojanowski with Sunny Biodiscovery. Separate funding and conflict details were not available in the retrieved publisher abstract.
  3. Fanning JE, McGee SA, Ibrahim OI. Human Clinical Trials Using Topical Bakuchiol Formulations for the Treatment of Skin Disorders: A Systematic Review. Journal of Drugs in Dermatology. 2024;23(4):239–243. doi:10.36849/JDD.7763. PMID:38564402.Tier 1Supports: Systematic search through 28 August 2022; 15 trials, including ageing, acne and post-inflammatory pigmentation, with heterogeneous designs and frequent combination products. Abstract-level appraisal only.Funding / interest: Funding and author conflicts were not reported in the retrieved PubMed abstract; full-text disclosure was not verified.
  4. Poláková K, Fauger A, Sayag M, Jourdan E. A dermocosmetic containing bakuchiol, Ginkgo biloba extract and mannitol improves the efficacy of adapalene in patients with acne vulgaris: result from a controlled randomized trial. Clinical, Cosmetic and Investigational Dermatology. 2015;8:187–191. doi:10.2147/CCID.S81691. PMID:25914553.Tier 2Supports: 111 participants, facial acne, 56 days, multi-active cream plus adapalene versus vehicle plus adapalene; inflammatory lesion benefit belongs to the complete regimen.Funding / interest: Laboratoire Bioderma funded the trial; Fauger, Sayag and Jourdan were employees. Poláková reported no financial interest. Medical writing assistance was acknowledged.
  5. Raison-Peyron N, Dereure O. A new case of contact dermatitis to bakuchiol in a cosmetic cream. Contact Dermatitis. 2020;82(1):61–62. doi:10.1111/cod.13387.Tier 3Supports: Existence of a published clinical report of contact dermatitis to bakuchiol in a cosmetic cream. Publisher title/record retrieved; case details were not available and are not claimed.Funding / interest: Publisher page states no conflicts of interest. Separate study funding was not visible; full case text was not retrieved.
  6. NHS. Contact dermatitis. Reviewed 3 May 2023. Accessed 16 September 2026.Tier 4Supports: Recognition of contact dermatitis, avoidance of the causal irritant/allergen, and assessment of persistent, recurrent or severe symptoms.Funding / interest: NHS patient guidance; no product sponsor or page-specific funding disclosure stated. Displayed next-review date had passed at access.
  7. NHS. Acne. Reviewed 3 January 2023. Accessed 16 September 2026.Tier 4Supports: Pharmacy advice for mild acne and GP assessment for moderate/severe disease, nodules/cysts, unsuccessful initial treatment or substantial distress.Funding / interest: NHS patient guidance; no product sponsor or page-specific funding disclosure stated. Displayed next-review date had passed at access.